Research programme: TYK2 inhibitors - Atomwise
Latest Information Update: 05 Oct 2023
At a glance
- Originator Atomwise
- Class Anti-inflammatories; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Inflammation
Most Recent Events
- 05 Oct 2023 Atomwise has patents pending for AtomNet® technology, before October 2023 (Atomwise website, October 2023)
- 04 Oct 2023 TYK2 targeting therapeutics are available for licensing as of 04 Oct 2023. https://www.atomwise.com/contact/ (Atomwise website, October 2023)
- 04 Oct 2023 Atomwise has patent protection for AtomNet® technology, before October 2023 (Atomwise website, October 2023)